Literature DB >> 3311223

Retroviral-mediated gene transfer into mammalian cells.

D B Kohn1, P W Kantoff, M A Eglitis, J R McLachlin, R C Moen, E Karson, J A Zwiebel, A Nienhuis, S Karlsson, R O'Reilly.   

Abstract

Retroviruses may be used as genetic vectors to transfer genes into mammalian cells with high efficiency. We have shown that the N2 vector will transfer a functional bacterial gene for neomycin resistance (NeoR) into more than 80% of mouse spleen foci. A derivative of the N2 vector was constructed to study transfer and expression of the human gene for adenosine deaminase (ADA) in mammalian lymphoid and hematopoietic stem cells. This vector, termed SAX, contains the human ADA cDNA with an SV40 promoter in addition to the NeoR gene. The SAX vector was found to efficiently transfer and express the ADA gene in an ADA-deficient human T-cell line. Gene transfer by SAX using an autologous nonhuman primate bone marrow transplant model resulted in expression of the human ADA gene in peripheral blood cells of treated animals. Human bone marrow treated with SAX produced 1%-2% of colonies in vitro that were expressing the vector genes. Transfer of genes into circulating hematopoietic stem cells of fetal sheep in utero was most efficient; vector gene expression was evident in 20%-40% of hematopoietic colonies. Therefore, retroviral vectors are capable of transferring functional genes into a wide variety of mammalian lymphoid and hematopoietic cells. Such vectors may be useful for clinical trials of gene therapy, that is, the correction of genetic diseases by insertion of a normal gene into a patient's defective cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3311223

Source DB:  PubMed          Journal:  Blood Cells        ISSN: 0340-4684


  7 in total

Review 1.  Gene therapy of primary immunodeficiencies.

Authors:  F Candotti; R M Blaese
Journal:  Springer Semin Immunopathol       Date:  1998

2.  Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent.

Authors:  G M Springett; R C Moen; S Anderson; R M Blaese; W F Anderson
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

3.  Lymphocytes as cellular vehicles for gene therapy in mouse and man.

Authors:  K Culver; K Cornetta; R Morgan; S Morecki; P Aebersold; A Kasid; M Lotze; S A Rosenberg; W F Anderson; R M Blaese
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells.

Authors:  S Morecki; E Karson; K Cornetta; A Kasid; P Aebersold; R M Blaese; W F Anderson; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.

Authors:  Bryanna Reinhardt; Omar Habib; Kit L Shaw; Elizabeth Garabedian; Denise A Carbonaro-Sarracino; Dayna Terrazas; Beatriz Campo Fernandez; Satiro De Oliveira; Theodore B Moore; Alan K Ikeda; Barbara C Engel; Gregory M Podsakoff; Roger P Hollis; Augustine Fernandes; Connie Jackson; Sally Shupien; Suparna Mishra; Alejandra Davila; Jack Mottahedeh; Andrej Vitomirov; Wenzhao Meng; Aaron M Rosenfeld; Aoife M Roche; Pascha Hokama; Shantan Reddy; John Everett; Xiaoyan Wang; Eline T Luning Prak; Kenneth Cornetta; Michael S Hershfield; Robert Sokolic; Suk See De Ravin; Harry L Malech; Frederic D Bushman; Fabio Candotti; Donald B Kohn
Journal:  Blood       Date:  2021-10-14       Impact factor: 25.476

Review 6.  Improvements in Gene Editing Technology Boost Its Applications in Livestock.

Authors:  Iuri Viotti Perisse; Zhiqiang Fan; Galina N Singina; Kenneth L White; Irina A Polejaeva
Journal:  Front Genet       Date:  2021-01-08       Impact factor: 4.599

Review 7.  Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells.

Authors:  Farnaz Faridi; Kanagaraju Ponnusamy; Isabell Quagliano-Lo Coco; Linping Chen-Wichmann; Manuel Grez; Reinhard Henschler; Christian Wichmann
Journal:  Front Genet       Date:  2013-11-28       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.